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Application of Area Scaling Analysis to
Identify Natural Killer Cell and Monocyte
Involvement in the GranToxiLux Antibody
Dependent Cell-Mediated Cytotoxicity Assay
Justin Pollara,1* Chiara Orlandi,2 Charles Beck,1 R. Whitney Edwards,1 Yi Hu,2 Shuying Liu,3
Shixia Wang,3 Richard A. Koup,4 Thomas N. Denny,5 Shan Lu,3 Georgia D. Tomaras,1
Anthony DeVico,2 George K. Lewis,2 Guido Ferrari1
 Abstract
Several different assay methodologies have been described for the evaluation of HIV or
SIV-specific antibody-dependent cell-mediated cytotoxicity (ADCC). Commonly used
assays measure ADCC by evaluating effector cell functions, or by detecting elimination of
target cells. Signaling through Fc receptors, cellular activation, cytotoxic granule
exocytosis, or accumulation of cytolytic and immune signaling factors have been used to
evaluate ADCC at the level of the effector cells. Alternatively, assays that measure killing
or loss of target cells provide a direct assessment of the specific killing activity of anti-
bodies capable of ADCC. Thus, each of these two distinct types of assays provides infor-
mation on only one of the critical components of an ADCC event; either the effector cells
involved, or the resulting effect on the target cell. We have developed a simple modifica-
tion of our previously described high-throughput ADCC GranToxiLux (GTL) assay that
uses area scaling analysis (ASA) to facilitate simultaneous quantification of ADCC activ-
ity at the target cell level, and assessment of the contribution of natural killer cells and
monocytes to the total observed ADCC activity when whole human peripheral blood
mononuclear cells are used as a source of effector cells. The modified analysis method
requires no additional reagents and can, therefore, be easily included in prospective stud-
ies. Moreover, ASA can also often be applied to pre-existing ADCC-GTL datasets. Thus,
incorporation of ASA to the ADCC-GTL assay provides an ancillary assessment of the
ability of natural and vaccine-induced antibodies to recruit natural killer cells as well as
monocytes against HIV or SIV; or to any other field of research for which this assay is
applied. VC 2018 The Authors. Cytometry Part A published by Wiley Periodicals, Inc. on behalf of ISAC.
 Key terms
natural killer cells; monocytes; antibody-dependent cell-mediated cytotoxicity;
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THERE has been a recent increase of interest in evaluating HIV/SIV-specific non-
neutralizing antibody responses, including those that mediate antibody-dependent
cell-mediated cytotoxicity (ADCC). Focus on the non-neutralizing Fc-mediated anti-
viral activities of antibodies has largely been a result of the identification of ADCC
responses as associated with the reduced risk of HIV-1 infection observed in the
RV144 clinical trial (1), reduced vertical transmission of HIV-1 via breast milk (2),
and in protection from SIV and SHIV infection in passive and active immunization
trials conducted in nonhuman primates (NHPs) (3–6). Several different types of
nonradioisotope-based assays have been developed to either semi-quantitatively or
quantitatively measure the HIV/SIV-specific ADCC activity of serum, plasma,
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mucosal samples, or purified antibodies [reviewed in Ref. 7].
We have previously described a high-throughput quantitative
flow cytometry-based assay that allows for detection of the
proteolytic activity of Granzyme B (GzB) at the single cell
level to identify target cells that have received a cytotoxic hit
as a result of antigen-specific antibody-Fc receptor interac-
tions (8). We and others have broadly applied this assay, the
ADCC-GranToxiLux assay (ADCC-GTL), to the measure of
HIV- or SIV-specific antibody responses generated by natural
infection or by active and passive immunization strategies
(6,9–37).
Here, we describe a simple modification of our original
ADCC-GTL assay that uses Area Scaling Analysis (ASA)
(38–40) to discriminate between ADCC mediated by natural
killer (NK) cells, and non-ADCC interactions between mono-
cytes and target cells when whole human peripheral blood
mononuclear cells (PBMC) are used as a source of effector
cells. Thus, this GTL-ASA assay can be used to evaluate the
ADCC activity of antibody samples while simultaneously pro-
viding ancillary assessment of the type of cells recruited by
ADCC antibodies, which can be used as an additional metric
to characterize the natural and vaccine-induced ADCC
responses to HIV or SIV. The incorporation of ASA to the
ADCC-GTL assay can be easily included in prospective stud-
ies, and can also often be applied to pre-existing ADCC-GTL
datasets.
METHODS
Human Ab Samples
HIV-1 seronegative and seropositive plasmas were
obtained from patients enrolled in studies conducted by the
Duke Center for HIV and AIDS Vaccine Immunology.
Vaccinee plasma samples were obtained from participants in
Groups A (n5 2) and B (n5 2) of the DP6-001 HIV vaccine
phase 1 trial, a multiclade DNA prime and HIV-envelope
gp120 protein boost vaccine regimen that elicited cross-
subtype ADCC responses (10,41). All human samples were
collected in accordance with protocols approved by the local
Institutional Review Boards (IRB). The HIV IgG immuno-
globulin preparation (HIVIG) (42) was obtained from the
NIH AIDS Research and Reagent Program. The HIV-1 enve-
lope specific monoclonal antibodies (mAbs) used include:
C11 and A32, which bind distinct conformational epitopes in
the Cluster A region of gp120 (43,44); VRC01, which binds to
the CD4 binding site (45); 2G12, which binds a gp120 outer
domain glycan region (46), and N10-U1 and 7B2, which tar-
get the immunodominant region of gp41 (47,48). All mAbs
were produced using recombinant techniques, and were
generated using both a natural human IgG1 constant region,
and IgG1 containing alanine substitutions (S298A, E333A,
K334A) designed to enhance binding to Fcc-receptor IIIa
(FccR3A) (49). The S298A mutation also acts to decrease
affinity for Fcc-receptor IIa and IIb (FccR2A and B) (49).
HIV-1 negative polyclonal human IgG (Gammagard S/D; Bax-
ter Healthcare; Westlake Village, CA) and the humanized
respiratory syncytial virus (RSV) specific mAb Synagis
VR
(IgG1k; palivizumab; MedImmune, LLC; Gaithersburg, MD)
were used as negative controls. Plasma samples were tested
after fivefold serial dilutions starting at 1:50, and mAbs were
tested after fivefold serial dilution resulting in a concentration
range of 10 lg/ml to 3 ng/ml.
Target Cells
A clonal isolate of the CEM.NKRCCR5 CD4
1 T cell line
[NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH:
from Dr. Alexandra Trkola (50)] was used as the source of tar-
get cells. The CEM.NKRCCR5 cells were used after coating with
a recombinant HIV-1 gp120 protein representing the envelope
of the subtype B BaL or SF162 (GenBank No. M68893 and
AAT67508, respectively; Immune Technology Corp, NY), or
after infection with an infectious molecular clone (IMC) virus
representing HIV-1 BaL and encoding a Renilla luciferase
reporter gene (51). The optimal amount of gp120 for coating
the target cells was determined by competing the binding of
FITC-conjugated CD4 Leu3A antibody (clone SK3; Catalog
no. 340133; Final dilution 1:5, BD Bioscience, San Jose, CA)
to the CD4 receptor expressed on the surface of the cell line as
previously described (8). Infections with the HIV-1 BaL IMC
were performed by incubation with DEAE-Dextran as previ-
ously described (8), and were monitored by measuring lucifer-
ase activity and determining the frequency of cells expressing
intracellular p24 using standard intracellular staining meth-
ods. >75% of the viable target cells used in assays were p24
positive.
Effector Cell Populations
PBMC obtained from a HIV-seronegative donor with the
heterozygous 158F/V and 131H/R genotypes for FccR3A and
FccR2A, respectively, were used for all experiments except
those designed to investigate how different FccR3A and
FccR2A genotypes affect ASA. For these studies, PBMC were
obtained from six HIV-seronegative donors with the following
combinations of FccR3A and FccR2A alleles: 158V/V 131H/H,
158F/F 131H/H, 158V/V 131R/R, 158F/F 131R/R, 158V/V
131H/R, 158F/F 131H/R. All blood donations were collected
under informed consent according to the appropriate
IRB-approved protocols. Blood was processed and used or
cryopreserved within 8 h of collection. Cells were counted for
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viability and adjusted to the proper concentration to obtain
an effector to target cell ratio of 30:1. For assays performed
with cryopreserved PBMC the cells were thawed and rested
overnight at 2 3 106 cell/ml in RPMI1640 medium supple-
mented with 10% FBS at 378C and 5% CO2 prior to use in the
assay.
For depletion experiments, NK cells or monocytes were
removed from PBMC using magnetic beads coated with anti-
human CD56 antibodies or anti-human CD14 antibodies,
respectively, according to manufacturer recommended proto-
cols (Miltenyi Biotec, Bergisch Gladbach, Germany). PBMC
incubated with biotin-coated magnetic beads (Miltenyi
Biotec) were used as a negative control to account for any
nonspecific depletion of cells associated with the magnetic
bead isolation procedure. The purity of each depleted cell
population was confirmed by flow cytometry after cell-surface
staining with aqua fluorescent LIVE/DEAD Fixable Stain
(Thermo Fisher Scientific, Waltham, MA) and the following
panel of antibodies: PE-TR-conjugated anti-CD3 (clone S4.1/
7D6; Catalog no. MHCD0317; Final dilution 1:20, Thermo
Fisher Scientific, Waltham, MA), PE-TR-conjugated anti-
CD19 (clone SJ25-C1; Catalog no. MHCD1917; Final dilution
1:20, eBioscience, Waltham, MA), APC-conjugated anti-CD32
(clone 6C4; Catalog no. 17–0329-42; Final dilution 1:20,
eBioscience/Thermo Fisher Scientific, Waltham, MA), APC-
Cy7-conjugated anti-CD14 (clone MuP9; Catalog no. 557831;
Final dilution 1:80, BD Bioscience, San Jose, CA), PacBlue-
conjugated anti-CD16 (clone 3G8; Catalog no. 558122; Final
dilution 1:80, BD Bioscience, San Jose, CA), PE-Cy7-
conjugated anti-CD56 (clone NCAM16.2; Catalog no. 335809;
Final dilution 1:80, BD Bioscience, San Jose, CA), FITC-
conjugated anti-CD64 (clone 10.1; Catalog no. 555527; Final
dilution 1:5, BD Bioscience, San Jose, CA), and PE-conjugated
anti-CD89 (clone A59; Catalog no. 555686; Final dilution
1:10, BD Bioscience). Purity staining confirmed a >90%
reduction in cell populations targeted for depletion. Where
indicated, experiments were performed using the NK-92 natu-
ral killer cell line, engineered to express human CD16
(CD16.NK-92; Conkwest Inc., Encinitas, CA) or the THP-1
monocyte like cell line (ATCC TIB-202 cells, ATCC, Manassas,
VA) as effector cells.
ADCC-GTL Assay
The ADCC-GTL assay was performed as previously
described (8). Briefly, coated or infected target cells were
labeled with TFL4 and the viability marker NFL1 (both from
OncoImmunin, Gaithersburg, MD, each at final dilution of
1:1,000). After counting and washing, 104 target cells per well
were added to 96-well V-bottom plates and incubated with
the Granzyme B (GzB) substrate (OncoImmunin) and
effector cells for 5 min at room temperature. The antibodies
(plasma or mAbs) were then added and the plate was incu-
bated an additional 15 min at room temperature, then for 1 h
at 378C 5% CO2 following centrifugation for 1 min at 300 g.
For experiments that included staining for CD14 as described
in the text, after incubation the plates were washed with 1%
FBS PBS wash buffer, and PE-conjugated anti-CD14 antibody
(clone MuP9, Catalog no. 562691; Final dilution 1:20, BD
Biosciences, San Jose, CA) was added to each well. The plates
were then incubated for 30 min at 48C and subsequently
washed three times with 1% FBS PBS wash buffer. Well
contents were then re-suspended in 150 ml wash buffer and
acquired directly with BD Fortessa flow cytometer (BD Biosci-
ences, San Jose, CA) within 4 h using the High Throughput
Sampler (HTS, BD Biosciences). The cytometer is rigorously
maintained under quality control procedures regularly per-
formed as described by Perfetto et al. (52). The signal for each
fluorophore was detected using: 1) 640 nm/40 mW laser and
660/20 filter for TFL4; 2) 405 nm/50 mW laser and 450/50 fil-
ter for NFL1; 3) 488 nm/50 mW laser and the combination of
505LP with 530/30 filters for the GzB substrate. Prior to
acquisition with FACSDiva software (BD Biosciences), the
area scaling factor was adjusted to ensure that cell singlets
(CEM.NKRCCR5 CD4
1 T cells) indicated equivalent ratios of
FSC-H and FSC-A. Flow cytometry data analysis was per-
formed using FlowJo 9.9.4 software (FlowJo, LLC., Ashland
OR).
ADCC-Luc Assay
ADCC activity was also determined by a luciferase (Luc)-
based assay as previously described (17). CEM.NKRCCR5 tar-
get cells infected with HIV-1 IMC encoding Renilla luciferase
were incubated with PBMC effector cells and antibodies in 1=2
area opaque flat bottom plates for 30 min at room tempera-
ture in duplicate wells. The plates were then centrifuged for 1
min at 300g, and subsequently incubated for an additional
5.5 h at 378C 5% CO2. ADCC activity, reported as percent
specific killing, was calculated from the change in Relative
Light Units (RLU; ViviRen luciferase assay; Promega,
Madison, WI) resulting from the loss of intact target cells in
wells containing effector cells, target cells, and plasma or mAb
samples compared to amounts in control wells containing
target cells and effector cells alone according to the following
formula: percent specific killing5 [(number of RLU of target
and effector well—number of RLU of test well)/number of
RLU of target and effector well] 3100.
GzB1 Target Cell Sorting and Fluorescent Confocal
Microscopy
The ADCC-GTL assay with subsequent surface staining
using PE-conjugated anti-CD14 was performed as described
above. Well contents were transferred to flow cytometry tubes
and processed using a BD FACSAria II cell sorter. Live, GzB1
target cells were sorted (TFL41, NFL12, GzB1) using a 100
lm nozzle, to permit collection of both single cells and stable
cell–cell conjugates. The sorted cell population was concen-
trated by centrifugation, transferred to 8-well chamber slides
and incubated for 30 min at 378C 5% CO2 to allow the cells to
form a monolayer on the glass bottom of the slides. The
sorted cells were then visualized using a Zeiss Laser Scanning
Microscope (LSM) 5 DUO. Four laser beams with wavelengths
at 405 nm, 488 nm, 543 nm, and 633 nm were used to excite
the fluorophore. Representative well images were captured
and analyzed using Zeiss, ZEN software (Zeiss, Oberkochen,
Germany).
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RESULTS
Evaluation of CD14 on the Surface of ADCC Target
Cells in the ADCC-GTL Assay
We have previously demonstrated that the ADCC anti-
body responses detectable in the plasma of HIV infected indi-
viduals measured using the ADCC-GTL assay were primarily
dependent on the recruitment of NK cells present in the
PBMC samples used as a source of effector cells in vitro (8).
However, recent evidence for the role of monocytes as effec-
tors in the rapid and fluorometric ADCC assay (RFADCC)
(53) prompted us to reevaluate the potential contribution of
monocytes to ADCC activity as measured in the GTL assay.
To determine if monocytes are involved in antibody-
dependent interactions with target cells in the ADCC-GTL
assay, we modified our protocol to include surface staining of
CD14 using a PE conjugated anti-CD14 antibody after incu-
bation of target cells with effector cells in presence of anti-
bodies. This approach allowed us to identify a population of
cells that may represent either target cells that have interacted
with monocytes resulting in transfer of cell-surface CD14 via
antibody-mediated trogocytosis as has been described for
the outcome of RFADCC (53,54), or monocytes that have
obtained fluorescently labeled target cell membranes via
phagocytosis. As shown in Figure 1A,B, approximately 15% of
CD41 T cells targeted for ADCC (cells expressing active Gran-
zyme B, GzB1) were positive for cell surface CD14 after incu-
bation with PBMC and chronic HIV seropositive plasma or
plasma from a HIV-1 controller (16.5% and 13.9% CD141,
respectively). In contrast, over 90% of active GzB1 T cell tar-
gets were identified as positive for cell-surface CD14 when
ADCC assays were performed with the HIV envelope mAb
C11, specific for epitope within the 7-stranded-ß sandwich of
gp120 Cluster A epitope region (40,55) (Fig. 1C). Importantly,
the CD141 cell population was restricted to those target cells
positive for active GzB, no CD14 was observed on target cells
that were GzB- (Fig. 1D) or in wells containing target cells
only (not shown). Low background levels of ADCC activity,
and thus very few CD141 target cells (<50 total CD141 GzB1
cells) were observed with the RSV-specific mAb Palivizumab
(Fig. 1E). These data demonstrate that specific antibody-
dependent interactions between monocytes and target cells
can contribute to the total events measured as ADCC activity
in the ADCC-GTL assay.
Conventional NK-Dependent ADCC and Monocyte-
Dependent Non-ADCC Activity Can Be Differentiated
by Unique Area Scaling Properties
Monocytes and cell conjugates can be discriminated from
single target cells by unique forward light scatter properties.
We applied ASA to GzB1 events in the ADCC-GTL assay to
explore whether monocytes or monocyte–target cell conju-
gates were being included in the GzB1 gate used to define
ADCC activity. We defined two gates using ASA (Fig. 2A).
The first gate (shown in red) includes cells with equivalent
ratios of forward scatter height (FSC-H) and area (FSC-A).
Events that fall within this gate are typically considered cell
singlets (38–40). The second gate (show in green) includes
events that are biased toward higher FSC-A relative to FSC-H,
a property associated with amorphously shaped cells or cell
conjugates (38–40). We applied this new gating strategy to
ADCC assays performed with whole PBMC, PBMC depleted
of CD141 cells (removing monocytes), and PBMC depleted
of CD561 cells (removing NK cells). Depletion with biotin-
coated beads was used as a negative control to account for any
nonspecific depletion of cells associated with the magnetic
bead isolation procedure. Depletion of CD561 cells largely
abrogated ADCC activity (>85% reduction of maximum
observed activity) of plasma collected from an HIV-1 infected
patient during the chronic stage of disease (Fig. 2B, left panel)
and from an HIV-1 controller (Fig. 2C, left panel), indicating
a predominant dependence on NK cells for ADCC by these
plasma samples. We next applied ASA to the GzB1 target
events for each of these assay conditions (Fig. 2B,C, right
panels) focusing on the dilution of plasma that indicated the
maximum observed ADCC response according to previous
titration experiments. For assays conducted with whole
PBMC we observed frequencies of cells in the singlet gate and
nonsinglet gate (monocyte/cell conjugates) that were consis-
tent with the contribution of NK cells and monocytes to total
ADCC activity as determined by depletion of these cell subsets
(>85% singlets, <15% nonsinglets). Similar distributions of
singlet and nonsinglet events were observed when the assays
were performed with PBMC depleted of CD141 cells. In con-
trast, when the assays were conducted with PBMC depleted of
CD561 cells the ASA indicated a bias toward events in the
nonsinglet gate. These data suggest that the GzB1 events
located in the singlet gate represent cells targeted by NK cells,
and events in the nonsinglet gate represent cells targeted by
monocytes. In support of this, depletion experiments
indicated that GzB activity measured by ADCC-GTL in assays
performed using the C11 mAb required the presence of
monocytes (Fig. 2D, left panel) and the ASA analysis of assays
conducted with whole PBMC indicated a bias toward events
in the nonsinglet gate, whereas when the assay was performed
after depletion of CD141 monocytes we observed a switch to
the majority of the GzB1 events falling into the singlet gate
(Fig. 2D, right panels). This indicates that the C11 mAb used
for these experiments preferentially recruited monocytes
when they were present in the effector cell population,
whereas with depletion of monocytes, NK cells were recruited.
We further explore the ability of plasma antibodies to
recruit a CD161 NK cell line (CD16.NK-92 cells) or the
THP-1 monocyte cell line as effector cells by applying ASA to
ADCC-GTL assays performed using these two types of effector
cells. We found that over 90% of the GzB1 events fall within
the gate defined as singlets when CD16.NK-92 cells are used
as effectors, while nearly 90% of the GzB1 events fall with the
nonsinglet gate when THP-1 monocytes were used as effector
cells (Supporting Information Fig. S1).
Collectively, these data suggest that ASA applied to the
GzB1 events collected with the ADCC-GTL assay can be used
to indicate the relative contribution of NK cells (singlet
events) and monocytes (nonsinglet events) to the total activity
measured using the ADCC-GTL assay.
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Figure 1. Presence of a CD141 subpopulation of HIV-1 gp120-coated CEM.NKRCCR5 target cells in the ADCC-GTL assay. (A) Gating strat-
egy used for analysis of ADCC activity and evaluation of CD14 on the surface of SF162 gp120-coated cells targeted for ADCC in ADCC-GTL
assays conducted with plasma from a chronically infected HIV-seropositive donor, (B) plasma from an HIV-1 virus controller, and (C) the
HIV-1 gp120 C1 region-specific mAb C11. Histograms in the far right panels indicate the detection of CD14 on the surface of GzB1 target
cells. (D) No CD14 was observed on the surface of GzB2 target cells. (E) The RSV-specific mAb Palivizumab was used as a negative control;
as expected the frequency of GzB1 events was low and very few CD141 cells were identified.
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Monocytes Can Form Ab-Dependent Cell-to-Cell
Interactions with gp120-Coated Target Cells in the
ADCC-GTL Assay
Our effector cell depletion experiments suggested that
GzB1 target cells that have undergone Ab-dependent interac-
tions with monocytes have unique area scaling properties
when compared to GzB1 target cells that have interacted with
NK cells. To further probe these monocyte and target cell
interactions, we combined surface staining for CD14, after
completion of the ADCC assay incubation, with ASA to deter-
mine if the CD14 positive subpopulation we have identified is
restricted to the nonsinglet gate. Using the plasma samples
collected from HIV-1 infected individuals and the C11 mAb
as the sources of ADCC-mediating antibodies we found that
the majority (>70%) of GzB1 target cells within the nonsing-
let gate were CD141 (Fig. 3A, green events and histograms),
whereas the GzB1 target cells that fell within the singlet gate
did not express cell-surface CD14 with any source of Ab
(Fig. 3A, red events and histograms). The presence of CD14
on the surface of GzB1 can occur via trogocytosis or phagocy-
tosis, but may also represent the formation of stable cell–cell
conjugates of target cells and monocytes. To determine if
Ab-dependent cell–cell conjugates were an outcome of inter-
actions between monocytes and target cells we performed the
ADCC-GTL assay with the C11 mAb, modified to include
CD14 surface staining after the 1 h incubation, and sorted
Figure 2. Application of Area Scaling Analysis (ASA) to the ADCC-GTL assay. (A) Gating strategy used for ASA of GzB1 SF162 gp120-
coated target cells in the modified ADCC-GTL assay. This gating strategy was used to identify singlet (red gate) and non-singlet (green
gate) GzB1 target cell events in ADCC-GTL assays performed with whole PBMC, PBMC depleted of CD141 cells, PBMC depleted of CD561
cells, and control PBMC depleted with biotin as sources of effector cells. ADCC antibody samples were plasma collected from an HIV-1
infected donor during chronic infection (B), plasma from an HIV-1 virus controller (C), and the C11 mAb (D). Data in the line graphs repre-
sents mean and SD from 3 independent experiments, and flow cytometry dot plots (B–D) include concatenated data from all 3
experiments.
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GzB1 target cells according to the gating strategy shown in
Figure 3B. Confocal microscopy was then performed on the
sorted GzB1 target cells as shown in Figure 3C. The combined
field shows that monocytes (CD141) and live target cells
(NFL12 TFL41) can form stable cell–cell conjugates. We also
confirmed that monocytes are able to acquire TFL4 from
Figure 3. Monocytes can form Ab-dependent cell-to-cell interactions with gp120-coated target cells in the ADCC-GTL assay. GzB1 target
cells that fall within the singlet gate do not have cell-surface CD14, while a large portion of GzB1 cells within the non-singlet gate have
cell-surface CD14. (A) Gating strategy and histograms indicating detection of CD14 in the singlet gate (red histograms) and the non-singlet
gate (green histograms) for ADCC-GTL assays performed with HIV-seropositive plasma and the C11 mAb as indicated. (B) An ADCC-GTL
assay was performed with PBMC effector cells, gp120-coated target cells, and the C11 mAb. The GzB1 events were sorted using the gates
shown (B), and evaluated by confocal microscopy after staining for CD14 (C). Both GzB1 singlet events and monocyte-target cell conju-
gates were observed.
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target cells during these cell–cell conjugate interactions, likely
via the process of trogocytosis. Confocal microcopy of assays
performed with the C11 mAb indicated the transfer of
TFL4 from the gp120-coated target cells to CD141 monocytes
(Supporting Information Fig. S2). This transfer was observed
when either whole PBMC (Supporting Information Fig. S2
panel A) or purified human monocytes (Supporting
Information Fig. S2 panel B) were used as effectors, suggesting
that ADCC-mediated NK-dependent apoptosis is not a
prerequisite for monocytes to acquire TFL4 from target cells.
In addition, nonconjugated monocytes positive for TFL4 were
also observed, suggesting the TFL4 fluorescent dye is
retained by monocytes after separation of monocyte–target
cell conjugates.
NK Cell ADCC-GTL Activity as Measured by Area
Scaling Analysis Correlates with Killing of HIV-1
Infected Cells in the Luciferase-Based (ADCC-Luc)
Assay
Having demonstrated that both conventional NK-
dependent ADCC, and non-ADCC activity resulting from
monocyte–target cell interactions including conjugate
formation and trogocytosis, contribute to the total activity
measured by the flow cytometry-based ADCC-GTL assay we
next sought to evaluate the association of NK-mediated and
monocyte-mediated activity as determined by ASA with lysis
of HIV-1 infected cells in the ADCC-Luc assay. We used a
panel of six HIV-specific monoclonal human IgG antibodies
produced via recombinant techniques as human IgG1, and
IgG1 with an engineered Fc region that includes alanine sub-
stitutions to enhance binding to FccR3A (S298A, E333A,
K334A), as sources of ADCC-mediating mAbs (49). We also
used the polyclonal HIV-specific IgG preparation, HIVIG.
The RSV-specific human IgG1 mAb Palivizumab and
Gammagard
VR
polyclonal human IgG preparation were used as
negative controls. As expected, only low background levels of
ADCC activity was observed with our negative controls (Pali-
vizumab, 1% GzB activity in ADCC-GTL, 0% specific killing
in ADCC-Luc; Gammagard, 0.7% GzB activity in ADCC-
GTL, 1.5% specific killing in ADCC-Luc). HIV-1BaL-infected
CD41 T cells were used as target cells for both the ADCC-
GTL and ADCC-Luc assays, and PBMC from a HIV-
seronegative donor with the heterozygous FccR3A 158F/V
phenotype served as the source of effector cells (55). ASA was
applied to ADCC-GTL data that represented the highest
observed total ADCC activity within the dilutions curves
tested for each antibody. As expected, optimization of the
antibody Fc region to improve binding to FccR3A resulted in
higher levels of NK-cell mediated ADCC (percentage of live,
GzB1 singlet events) as indicated by GTL-ASA for five out of
six tested mAbs (Fig. 4A). We observed a positive correlation
between the ability of antibodies to recruit NK cells for ADCC
activity with total ADCC activity in the ADCC-GTL assay
(Fig. 4B, Spearman r5 0.81, P< 0.001), as well as with
maximum observed specific killing of HIV-infected target cells
using the ADCC-Luc Assay (Fig. 4C, Spearman r5 0.80.
P< 0.001) (17). In contrast, we observed a negative
Figure 4. NK cell-mediated ADCC is associated with specific lysis
of HIV-infected cells. (A) Optimization of antibody Fc regions for
binding to FccR3A results in increased % NK cell dependent
ADCC directed against HIV-infected cells as measured by ASA in
the modified ADCC-GTL assay. (B) Total ADCC activity of the anti-
body panel shown in panel A measured using the ADCC-GTL
assay is positively associated with % NK cell dependent ADCC
(singlet gate). (C) The % NK cell dependent ADCC against HIV-
infected targets in the ADCC-GTL assay correlates with the maxi-
mum specific killing of HIV-infected target cells as measured by
the ADCC-Luc assay. ADCC-Luc assays were performed in dupli-
cate and are reported as mean and standard deviation.
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correlation between the ability of antibodies to recruit mono-
cytes and the maximum observed specific killing of HIV-
infected target cells in the ADCC-Luc Assay (Supporting
Information Fig. S3, Spearman r5-0.80, P< 0.001), sugges-
ting that recruitment of monocytes may result in trogocytosis,
phagocytosis, slower killing of target cells, or other antiviral
responses that are not discernable in the ADCC-Luc Assay.
These results demonstrate that the GTL-ASA assay data can be
used to inform on the type of effector cells recruited by anti-
bodies, thus providing an additional metric for evaluation of
HIV or SIV-specific Fc-mediated antibody responses.
ASA Is Unable to Differentiate Donor Cells Based on
FccR3A and FccR2A Single Nucleotide Polymorphisms
We have demonstrated that ASA-GTL can be used to
identify differences in the ability of antibodies to recruit NK
cells or monocytes for ADCC when applied within assays
performed with PBMC from the same donor. We next asked
whether ASA could be used to identify differential recruitment
of NK cells or monocytes resulting from single nucleotide
polymorphisms for FccR3A and FccR2A. To test this possibil-
ity, we performed ASA-GTL assays using cryopreserved
PBMC collected from six donors with the following alleles for
FccR3A and FccR2A, respectively: 158V/V 131H/H, 158F/F
131H/H, 158V/V 131R/R, 158F/F 131R/R, 158V/V 131H/R,
and 158F/F 131H/R. The percentages of total ADCC attrib-
uted to NK cells (Fig. 5A) or monocytes (Fig. 5B) at the
antibody concentration or plasma dilution representing the
maximum observed ADCC responses were determined by
ASA of GzB1 target as described above. In ADCC assays per-
formed with HIV-specific IgG1 mAbs A32, 2G12, and C11, or
with plasma samples collected from recipients of a candidate
DNA-prime protein-boost HIV-vaccine (10,41), we found
that NK cell-mediated ADCC (Fig. 5A) did not rank-order as
expected based on FccR3A genotype (56–61). Specifically, we
observed no bias toward recruitment of NK cells in assays per-
formed with PBMC from donors with the higher affinity
158V/V allelic variant of FccR3A when compared to donors
with the lower affinity 158F/F variant. Moreover, we did not
observe any discernable impact of FccR2A alleles on
monocyte-mediated ADCC (Fig. 5B). Thus, ASA can provide
information on antibodies when assays are performed with
the same PBMC, but is unlikely to provide information on
characteristics of donor effector cells for assays performed
with a set panel of antibodies and PBMC from multiple
donors representing different FccR phenotypes. This may be
related to intrinsic differences in frequencies and activation
states of circulating NK cells and monocytes amongst donors.
DISCUSSION
Multiple assay methodologies have been described and
applied to the evaluation of HIV or SIV-specific ADCC activ-
ity [reviewed in Ref. 7]. Assays such as the newly developed
FccR3A cell line reporter assays (Promega ADCC Reporter
Bioassay) and the CD107a degranulation/intracellular cyto-
kine assay (62) measure ADCC by detecting signaling through
Fc receptors, or cellular activation and/or production of anti-
viral and cytolytic factors by Fc receptor-bearing effector cells.
Thus, these assays are mainly intended to evaluate the effect of
ADCC responses at the level of the effector cell populations.
Other assays such as the ADCC-GTL assay (8), ADCC-Luc
assay (17,63), and the classic 51Cr release assay (64) assess the
effect of ADCC responses on the target cell populations by
detecting the initiation of apoptosis, or by measuring cytoly-
sis. Thus, each of these assays provides information on only
one of the critical components of an ADCC event; either the
effector cells involved, or the resulting effect on the target cell.
Obtaining information on both cell populations typically
Figure 5. ASA is unable to differentiate donor cells based on
FccR3A and FccR2A single nucleotide polymorphisms. The
ADCC-GTL assay was performed using HIV-specific IgG mAbs,
vaccinee plasma samples (n54), and PBMC collected from 6 dif-
ferent donors, all with unique allelic combinations of common
FccR3A and FccR2A single nucleotide polymorphisms. The per-
centage of the total maximum ADCC response attributed to NK
cells (A) and monocytes (B) was determined by ASA. Donor
FccR3A and FccR2A are grouped by phenotype as indicated by
the brackets below the X axis in panel A and B, respectively.
Data for the vaccinee samples (n54) represents the mean and
standard deviation.
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requires depletion of specific subsets of effector cells from
PBMC, the use of purified effector cell populations, or the use
of a combination of ADCC assay methodologies. Here we
have described a simple modification of the ADCC-GTL assay
that applies ASA to assess the ability of ADCC antibodies to
interact with NK cells and monocytes present in the PBMC
used as a source of effector cells. The inclusion of ASA in the
evaluation of the results obtained with ADCC-GTL assay
allows for simultaneous quantification of target cell recogni-
tion, and the relative recruitment of monocytes or NK cells by
ADCC antibodies.
The involvement of monocytes in HIV-specific ADCC
was highlighted by Kramski et al. through a detailed charac-
terization of the RFADCC assay (53). Interestingly, they found
that the cell population typically regarded as killed target cells
in this assay is primarily comprised of CD141 cells from the
effector cell population that have obtained some of fluorescent
dye used to identify the target cells. This may happen either as
a result of monocyte phagocytosis or by cell surface mem-
brane exchange via trogocytosis. Additional work is required
to fully define the biological mechanism detected with the
RFADCC assay, but it is clear from the work of Kramski et al.
that it does not strictly and solely measure NK cell-mediated
target cell lysis as initially thought. Antibody responses
measured by the RFADCC assay have been correlated with
reduced infection risk and virus control (2,4,65–70), sugges-
ting that antibody-mediated recruitment of monocytes may
be an important component of HIV-specific immune
responses warranting further study.
We have previously demonstrated that whole PBMC and
purified NK cells have similar ability to mediate ADCC as
measured by the ADCC-GTL assay, and the majority of the
observed HIV-specific ADCC activity was lost when PBMC
were depleted of CD561 cells or CD161 cells (8). These data
suggested that NK cells were the predominant cell type
involved in ADCC as detected by the ADCC-GTL assay using
plasma from naturally HIV-1-infected viremic subjects or SIV
infected nonhuman primates. To more carefully evaluate the
possible role of monocytes, we modified the ADCC-GTL assay
method to include cell surface staining with a fluorescent
anti-CD14 antibody as described for characterization of the
“killed” target cells in the RFADCC assay (53). We found that
the majority of target cells positive for active GzB after incuba-
tion with HIV-1 seropositive plasma lacked cell-surface CD14
as expected, whereas a population of GzB1 CD141 cells was
observed when assays were conducted with the Cluster
A-region specific mAb C11. We further confirmed these find-
ings by applying ASA in combination with specific depletion
of NK cells or monocytes from PBMC used as a source of
effector cells. We found that the population of GzB1 target
cells within the singlet gate lacked CD14 and were primarily
dependent on the presence of NK cells in the effector cell pop-
ulation. In contrast, the population biased toward higher
FSC-A relative to FSC-H, and associated with amorphously
shaped cells or cell conjugates, was primarily dependent on
the presence of monocytes. These nonsinglet events were
highly enriched for CD141 events within the target cell gate,
and confocal microscopy demonstrated the presence of GzB1
target cell–CD141 monocyte cell conjugates within this
population. Thus, we propose that ASA can be applied to the
ADCC-GTL assay to identify ADCC mediated by NK cells
(TFL41 GzB1 singlet events) and target cells that have
interacted with monocytes (TFL41 GzB1 nonsinglet events).
Our data also demonstrated that while ASA can provide infor-
mation on antibody-mediated recruitment of NK cells and
monocyte when assays are performed with the same PBMC, it
is unable to differentiate donor cells based on FccR3A and
FccR2A single nucleotide polymorphisms. This suggests that
ASA will be most informative when applied to datasets col-
lected using the same source of effector cells, and not across
datasets using effector cells collected from different donors.
Using a panel of HIV-specific mAbs, we demonstrated
that mAbs optimized for binding to FccR3A yielded higher
NK-mediated ADCC activity compared to monocyte-
mediated trogocytosis or phagocytosis. We also found that
NK-mediated ADCC was positively associated with higher
levels of total ADCC activity among the mAb panel, and
NK-mediated ADCC measured in the ADCC-GTL assay was
positively correlated with lysis of HIV-infected target cells as
measured by the ADCC-Luc assay. Additional work to
explore how GTL-ASA can inform our understanding of
HIV/SIV specific ADCC responses is ongoing. Importantly,
we recently applied GTL-ASA to a study aimed at identifying
correlates of protection from SHIV challenge following
active immunization in a NHP model (6). In this study, rhe-
sus macaques were immunized with a poxvirus prime and
protein boost vaccine regimen designed to improve on the
efficacy observed for the RV144 clinical trial (1,71). A com-
prehensive analysis of immune correlates of infection risk
identified the maximum NK cell-mediated ADCC activity
(measured using ASA-GTL) against target cells coated with a
subtype E gp120 isolate as a component of the immune
response correlated with decreased risk of infection (concor-
dance index 0.7, P< 0.05) after repeated low dose challenges.
These data suggest that ADCC mediated by NK cells may
contribute to protection from SHIV infection in the NHP
model system. We are currently studying the biology of
monocyte recruitment measured by GTL-ASA as our recent
data suggests that ADCC mediated by NK cells and
antibody-dependent recruitment of monocytes have distinct
physiological roles in immune responses to HIV/SIV infec-
tion. The interaction with monocytes may not lead to rapid
killing of target cells, but may result in trogocytosis, phago-
cytosis, delayed killing, or other yet unknown immune effec-
tor functions. The inclusion of ASA in the ADCC-GTL assay
can be used to help define the unique immunologic func-
tions of NK cell-mediated and monocyte-mediated antibody
responses in protection from HIV/SIV infection, or for the
control of viremia and disease progression. GTL-ASA can
also be used to explore the antibody-dependent contribution
of NK cells and monocytes to immune responses directed
against any other disease or malignancy for which this assay
platform is applied.
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